Skip to main content
PMC home page
Protein Science : A Publication of the Protein Society logoLink to Protein Science : A Publication of the Protein Society
. 1992 Jan;1(1):151–160. doi: 10.1002/pro.5560010115

The sequence HGLGHGHEQQHGLGHGH in the light chain of high molecular weight kininogen serves as a primary structural feature for zinc-dependent binding to an anionic surface.

R A DeLa Cadena 1, R W Colman 1
PMCID: PMC2142082  PMID: 1304876

Abstract

The histidine-glycine-rich region of the light chain of cleaved high molecular weight kininogen (HK) is thought to be responsible for binding to negatively charged surfaces and initiation of the intrinsic coagulation, fibrinolytic, and kinin-forming systems. However, the specifically required amino acid sequences have not been delineated. An IgG fraction of a monoclonal antibody (MAb) C11C1 to the HK light chain was shown to inhibit by 66% the coagulant activity and by 57% the binding of HK to the anionic surface of kaolin at a concentration of 1.5 microM and 27 microM, respectively. Proteolytic fragments of HK were produced by successive digestion with human plasma kallikrein and factor XIa (FXIa). Those polypeptides that bound tightly (Kd = 0.77 nM) to a C11C1 affinity column were eluted at pH 3.0 and purified by membrane filtration. On 15% SDS polyacrylamide electrophoresis, the approximate M(r) was 7.3 kDa (range 6.2-8.1 kDa). Based on N-terminal sequencing, this polypeptide (1(2)), which extends from the histidine residue 459 to a lysine at position 505, 509, 511, 512, 515, or 520, inhibits by 50% the coagulant activity expressed by HK at a concentration of 22 microM. The synthetic peptide HGLGHGH representing the N-terminal of the 1(2)) fragment was synthesized, tested, and found at 4 mM to inhibit the procoagulant activity of HK 50%. A synthetic heptadecapeptide, HGLGHGHEQQHGLGHGH (residues 459-475) included within the 1(2) fragment, and with the ability to bind zinc, inhibited 50% of the HK coagulant activity at a concentration of 325 microM in the absence and presence of added Zn2+ (30 microM). The specific binding of 125I-HK to a negatively charged surface (kaolin) was inhibited 50% by unlabeled HK (5 microM). HGLGHGH, at a concentration of 7.0 mM, inhibited the binding to kaolin by 50%. The heptadecapeptide inhibited the specific binding of 125I-HK to kaolin by 50%, at a concentration of 2.3 mM, in the absence of Zn2+. In contrast, when Zn2+ was added, the concentration to achieve 50% inhibition decreased to 630 microM, indicating that Zn2+ was required to attain a favorable conformation for binding. Moreover, the 1(2) fragment was found to inhibit 50% of the 125I-HK binding to kaolin at a concentration of 380 microM. These results suggest that residues contained within the 1(2) fragment, notably HGLGHGHEQQHGLGHGH, serves as a primary structural feature for binding to a negatively charged surface.

Full Text

The Full Text of this article is available as a PDF (1.6 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bennett J. S., Shattil S. J., Power J. W., Gartner T. K. Interaction of fibrinogen with its platelet receptor. Differential effects of alpha and gamma chain fibrinogen peptides on the glycoprotein IIb-IIIa complex. J Biol Chem. 1988 Sep 15;263(26):12948–12953. [PubMed] [Google Scholar]
  2. Colman R. W., Müller-Esterl W. Subcommittee on contact activation. Nomenclature of kininogens. Thromb Haemost. 1988 Oct 31;60(2):340–341. [PubMed] [Google Scholar]
  3. Colman R. W. Surface-mediated defense reactions. The plasma contact activation system. J Clin Invest. 1984 May;73(5):1249–1253. doi: 10.1172/JCI111326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. De La Cadena R. A., Baglia F. A., Johnson C. A., Wenk R. E., Amernick R., Walsh P. N., Colman R. W. Naturally occurring human antibodies against two distinct functional domains in the heavy chain of FXI/FXIa. Blood. 1988 Nov;72(5):1748–1754. [PubMed] [Google Scholar]
  5. Greengard J. S., Heeb M. J., Ersdal E., Walsh P. N., Griffin J. H. Binding of coagulation factor XI to washed human platelets. Biochemistry. 1986 Jul 1;25(13):3884–3890. doi: 10.1021/bi00361a022. [DOI] [PubMed] [Google Scholar]
  6. Gustafson E. J., Schutsky D., Knight L. C., Schmaier A. H. High molecular weight kininogen binds to unstimulated platelets. J Clin Invest. 1986 Jul;78(1):310–318. doi: 10.1172/JCI112567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ikari N., Sugo T., Fujii S., Kato H., Iwanaga S. The role of bovine high-molecular-weight (HMW) kininogen in contact-mediated activation of bovine factor XII: interaction of HMW kininogen with kaolin and plasma prekallikrein. J Biochem. 1981 Jun;89(6):1699–1709. doi: 10.1093/oxfordjournals.jbchem.a133370. [DOI] [PubMed] [Google Scholar]
  8. Kato H., Nagasawa S., Iwanaga S. HMW and LMW kininogens. Methods Enzymol. 1981;80(Pt 100):172–198. doi: 10.1016/s0076-6879(81)80017-1. [DOI] [PubMed] [Google Scholar]
  9. Kerbiriou D. M., Griffin J. H. Human high molecular weight kininogen. Studies of structure-function relationships and of proteolysis of the molecule occurring during contact activation of plasma. J Biol Chem. 1979 Dec 10;254(23):12020–12027. [PubMed] [Google Scholar]
  10. Mandle R. J., Colman R. W., Kaplan A. P. Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. Proc Natl Acad Sci U S A. 1976 Nov;73(11):4179–4183. doi: 10.1073/pnas.73.11.4179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Mori K., Nagasawa S. Studies on human high molecular weight (HMW) kininogen. II. Structural change of HMW kininogen by the action of human plasma kallikrein. J Biochem. 1981 May;89(5):1465–1473. doi: 10.1093/oxfordjournals.jbchem.a133339. [DOI] [PubMed] [Google Scholar]
  12. Retzios A. D., Rosenfeld R., Schiffman S. Effects of chemical modifications on the surface- and protein-binding properties of the light chain of human high molecular weight kininogen. J Biol Chem. 1987 Mar 5;262(7):3074–3081. [PubMed] [Google Scholar]
  13. Schmaier A. H., Schutsky D., Farber A., Silver L. D., Bradford H. N., Colman R. W. Determination of the bifunctional properties of high molecular weight kininogen by studies with monoclonal antibodies directed to each of its chains. J Biol Chem. 1987 Jan 25;262(3):1405–1411. [PubMed] [Google Scholar]
  14. Scott C. F., Silver L. D., Purdon A. D., Colman R. W. Cleavage of human high molecular weight kininogen by factor XIa in vitro. Effect on structure and function. J Biol Chem. 1985 Sep 5;260(19):10856–10863. [PubMed] [Google Scholar]
  15. Scott C. F., Silver L. D., Schapira M., Colman R. W. Cleavage of human high molecular weight kininogen markedly enhances its coagulant activity. Evidence that this molecule exists as a procofactor. J Clin Invest. 1984 Apr;73(4):954–962. doi: 10.1172/JCI111319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Shimada T., Kato H., Iwanaga S. Accelerating effect of zinc ions on the surface-mediated activation of factor XII and prekallikrein. J Biochem. 1987 Oct;102(4):913–921. doi: 10.1093/oxfordjournals.jbchem.a122132. [DOI] [PubMed] [Google Scholar]
  17. Sinha D., Koshy A., Seaman F. S., Walsh P. N. Functional characterization of human blood coagulation factor XIa using hybridoma antibodies. J Biol Chem. 1985 Sep 5;260(19):10714–10719. [PubMed] [Google Scholar]
  18. Sugo T., Ikari N., Kato H., Iwanaga S., Fujii S. Functional sites of bovine high molecular weight kininogen as a cofactor in kaolin-mediated activation of factor XII (Hageman factor). Biochemistry. 1980 Jul 8;19(14):3215–3220. doi: 10.1021/bi00555a018. [DOI] [PubMed] [Google Scholar]
  19. Tait J. F., Fujikawa K. Primary structure requirements for the binding of human high molecular weight kininogen to plasma prekallikrein and factor XI. J Biol Chem. 1987 Aug 25;262(24):11651–11656. [PubMed] [Google Scholar]
  20. Takagaki Y., Kitamura N., Nakanishi S. Cloning and sequence analysis of cDNAs for human high molecular weight and low molecular weight prekininogens. Primary structures of two human prekininogens. J Biol Chem. 1985 Jul 15;260(14):8601–8609. [PubMed] [Google Scholar]
  21. Thompson R. E., Mandle R., Jr, Kaplan A. P. Association of factor XI and high molecular weight kininogen in human plasma. J Clin Invest. 1977 Dec;60(6):1376–1380. doi: 10.1172/JCI108898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Wiggins R. C. Kinin release from high molecular weight kininogen by the action of Hageman factor in the absence of kallikrein. J Biol Chem. 1983 Jul 25;258(14):8963–8970. [PubMed] [Google Scholar]
  23. van Iwaarden F., de Groot P. G., Bouma B. N. The binding of high molecular weight kininogen to cultured human endothelial cells. J Biol Chem. 1988 Apr 5;263(10):4698–4703. [PubMed] [Google Scholar]

Articles from Protein science : a publication of the Protein Society are provided here courtesy of The Protein Society

RESOURCES